Photo used for representation purpose only.
| Photo Credit: Getty Images/iStock
The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 65 new drug formulations, and notified ceiling prices for 13 formulations.
The authority has fixed the prices of drugs used to treat Type 2 diabetes, high cholesterol, bacterial infections, and painkillers, whereas drugs with revised ceiling prices include vaccines for rabies, tetanus, and measles, among others, according to multiple notifications from the NPPA.
The decisions were taken at the authority’s 128th meeting on December 12.
Revising and fixing retail and ceiling prices is a routine exercise undertaken by the NPPA.
In a recent government notification, the retail prices of essential fixed-dose combination drugs (FCDs), including a combination of atorvastatin and ezetimibe tablets used to treat high cholesterol and triglyceride levels have been fixed. Other FCDs included in the list are combinations of dispersible amoxycillin and potassium clavulanate to treat bacterial infections, including sinusitis, and gliclazide and metformin hydrochloride, which are used to treat Type 2 diabetes. The list also includes dietary supplements such as oral cholecalciferol (Vitamin D3) tablets and antifungal itraconazole capsules.
The drugs for which ceiling prices have been revised include injectable immunoglobulins for rabies, tetanus, and measles.
Published – December 23, 2024 06:23 pm IST